[Influence of erythropoietin therapy on systolic function of myocardium in patients with cardiorenal syndrome on hemodialysis].
We observed 93 patients with CRS 2,4,5 types having anemia, systolic dysfunction of left ventricle (LV) - EF ≤45% and heart failure functional class (FC) II-IV (NYHA). All patients are under HD and were treated with EPO 3 times per week in a period of 6 months. We revealed improvement of LV EF 4,3 % and HF FC after EPO treatment and concluded that EPO therapy causes regression of LV hypertrophy, improves LV function and quality of life.